Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer

Código QR

Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer

Barbara Legius,1 Sandra Van Den Broecke,1 Inge Muylle,1 Vincent Ninane1,2 1Department of Pulmonology, Centre Hospitalier Universitaire Saint Pierre, 2Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium Abstract: Non-small cell lung cancer can exhibit driver oncogenes, in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Legius B, Van Den Broecke S, Muylle I, Ninane V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Epidermal growth factor receptor (EGFR) mutation Anaplastic lymphoma kinase (ALK) translocation Africa Lung adenocarcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d464a303cfb346a08c223fa98621e3ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study
por: Katrine Fjaellegaard, et al.
Publicado: (2021)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)

Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
por: Anna M. Wulf, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”
por: Umberto Caterino, et al.
Publicado: (2021)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang W, et al.
Publicado: (2020)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Elli Narvi, et al.
Publicado: (2018)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Yangchun Gu, et al.
Publicado: (2021)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero Estela, et al.
Publicado: (2020)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang WT, et al.
Publicado: (2018)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
por: Yukari Tsubata, et al.
Publicado: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
por: Ling-Ling Kong, et al.
Publicado: (2017)

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
por: Adriana Petrazzuolo, et al.
Publicado: (2021)

Linfoma anaplástico de células grandes CD30 positivo cutáneo primario: reporte de un caso
por: Navarrete-Dechent,Cristián, et al.
Publicado: (2015)

Molecular genetic portrait of non-small cell lung cancer in Tambov region: regional experience
por: N. A. Ognerubov, et al.
Publicado: (2020)

Effect of brain radiotherapy strategies on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
por: Guangchuan Deng, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
por: Kazutaka Fujita, et al.
Publicado: (2021)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
por: Cristina Minnelli, et al.
Publicado: (2021)

Synthesis and computational study of 4-hydroxylbenzamide analogous as potential anti-breast cancer agent
por: Chia Hui Low, et al.
Publicado: (2022)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
por: Syahruddin E, et al.
Publicado: (2018)

Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
por: Haomin Zhang, et al.
Publicado: (2021)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios G, et al.
Publicado: (2021)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Caiyu Lin, et al.
Publicado: (2021)

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
por: Tomasz Marjanski, et al.
Publicado: (2021)

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
por: Xuan Zhou, et al.
Publicado: (2021)

Pneumonic-type lung adenocarcinoma with different ranges exhibiting different clinical, imaging, and pathological characteristics
por: Ji-wen Huo, et al.
Publicado: (2021)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee CS, et al.
Publicado: (2020)

ANALYSIS OF IMMUNOHISTOCHEMICAL EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN COLORECTAL CANCER
por: Ghazala Sadaf, et al.
Publicado: (2020)

Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells
por: Roy K, et al.
Publicado: (2015)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
por: Masatomo Ueda, et al.
Publicado: (2021)

Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs
por: Louise Pinet, et al.
Publicado: (2021)

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
por: Zhang Ying, et al.
Publicado: (2021)

Tumor de colisión: Metástasis de adenocarcinoma y linfoma folicular en un mismo ganglio linfático
por: García,Jorge, et al.
Publicado: (2009)